Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II talimogene laherparepvec in classic or endemic Kaposi sarcoma
2019-004403-12Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2020
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in Kaposi sarcoma (KS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Best overall response rate (BORR) of injected lesions. Started Jun 2020; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on 2019-004403-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004403-12.